Organization (Other)
Gruppo Oncologico Italiano di Ricerca Clinica
ClinicalTrials.gov lists Gruppo Oncologico Italiano di Ricerca Clinica as lead sponsor of 28 trials. It has 33 active development programs and 23 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 6 registered with a 2026 start date. The dashed outline is the pace from the 6 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Gruppo Oncologico Italiano di Ricerca Clinica: 28 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (16)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Lung Neoplasms | 8 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Carcinoma, Renal Cell | 3 |
| Colorectal Neoplasms | 3 |
| Kidney Neoplasms | 3 |
Showing 5 of 16 disease areas.
Trials by start year as sponsor or collaborator (17)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 6 |
| 2025 | 2 |
| 2024 | 2 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 2 |
| 2019 | 4 |
| 2018 | 1 |
| 2017 | 3 |
| 2016 | 2 |
Showing 10 of 17 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (33)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Atezolizumab 1200 MG in 20 ML Injection | Mesothelioma, Malignant | Phase 3 | 1 |
| Atezolizumab 1200 MG in 20 ML Injection | Mesothelioma | Phase 3 | 1 |
| Atezolizumab 1200 MG in 20 ML Injection | Lung Neoplasms | Phase 3 | 1 |
| ATEZOLIZUMAB | Lung Neoplasms | Phase 2 | 3 |
| ATEZOLIZUMAB | Small Cell Lung Carcinoma | Phase 2 | 2 |
Showing 5 of 33 active programs.
Approved assets (23)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Edoxaban | 1 |
| Interferon Alfa 2A | 1 |
| Interleukin 2 | 1 |
| ATEZOLIZUMAB | 3 |
| BEVACIZUMAB | 2 |
Showing 5 of 23 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 67% hit target (n=9) | 22% on time (n=9) |
Journals published in (63)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 19 |
| The Lancet. Oncology | 9 |
| The New England journal of medicine | 9 |
| Annals of oncology : official journal of the European Society for Medical Oncology | 8 |
| Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 7 |
Showing 5 of 63 journals.
Organization relationships (20)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Gruppo Oncologico Italia Meridionale | Co sponsors trial with | 2 |
| Istituto Toscano Tumori | Co sponsors trial with | 2 |
| Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente | Co sponsors trial with | 2 |
| YGHEA, CRO Division of Ecol Studio spa | Co sponsors trial with | 2 |
| Mipharm (Italy) | Co sponsors trial with | 1 |
Showing 5 of 20 relationships.
Latest dated events (33)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-14 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 33 events.
Biomarker capability evidence (118)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALK | Trial sponsor | Named in trial inclusion criteria |
| BRAF | Trial sponsor | Named in trial inclusion criteria |
| CD4 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 118 evidence rows.
Biomarkers this organization publishes on (10)
Shown in this order: most publications first.
Showing 5 of 10 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.